Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that it will present at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022.
|
CRANFORD, N.J., May 18, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc., ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that it will present at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022. Leonard Mazur, Chairman and CEO of Citius, will discuss the Company's recent business developments and upcoming milestones.
Interested parties may schedule 1-on-1 meetings with Citius management by registering through the event platform or contacting the Company's investor relations team. About Citius Pharmaceuticals, Inc. Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapies. The Company has two late-stage product candidates, Mino-Lok®, an antibiotic lock solution for the treatment of patients with catheter-related bloodstream infections (CRBSIs), which is currently enrolling patients in a Phase 3 Pivotal superiority trial, and I/ONTAK (E7777), a novel IL-2R immunotherapy for an initial indication in cutaneous T-cell lymphoma (CTCL), which has completed enrollment in its Pivotal Phase 3 trial. Mino-Lok® was granted Fast Track designation by the U.S. Food and Drug Administration (FDA). I/ONTAK has received orphan drug designation by the FDA for the treatment of CTCL and peripheral T-cell lymphoma (PTCL). Through its subsidiary, NoveCite, Inc., Citius is developing a novel proprietary mesenchymal stem cell treatment derived from induced pluripotent stem cells (iPSCs) for acute respiratory conditions, with a near-term focus on acute respiratory distress syndrome (ARDS) associated with COVID-19. For more information, please visit www.citiuspharma.com. Investor Relations for Citius Pharmaceuticals:
SOURCE Citius Pharmaceuticals, Inc. |
||||||||||||||
Company Codes: NASDAQ-SMALL:CTXR |
||||||||||||||
View original content to download multimedia:
